AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study NCT00075725 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00075725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00888524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GP in Physio
Description: manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
Study NCT00888524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GP in Physio plus DWR
Description: GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
Study NCT01500915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0,5mg intravitreal ranibizumab
Study NCT02101684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel 300mg BID
Study NCT03865745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Take one pack of the product (3g) once a day for 24 weeks
Study NCT03372460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active stimulation
Description: For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
Study NCT03372460 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
Study NCT03372460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR)
Description: Participants will undergo VR exposure to trauma-related context.
Study NCT03372460 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality (VR)
Description: Participants will undergo VR exposure to trauma-related context.
Study NCT03307161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic manual therapy
Description: Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
Study NCT01895231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (Monofer®)
Study NCT01895231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01728506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss and Exercise
Description: Internet delivered, behaviorally based weight loss and exercise intervention
Study NCT03222973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 (opicinumab)
Description: Administered as specified in the treatment arm
Study NCT03222973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT05121220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed retainer
Description: bonded lingual mandibular fixed retainer on frontal teeth 33-43
Study NCT05121220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable retainer
Description: thermoplastic vacuum-formed removable mandibular retainer
Study NCT00436423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, TS-1
Study NCT00581269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low-impact aerobic exercise
Description: subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
Study NCT00581269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low-calorie (low-fat) diet
Description: subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
Study NCT06355947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive cycling training
Description: Cycling training conducted with cognitive tasks
Study NCT06355947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive treadmill training
Description: Treadmill training conducted with cognitive tasks
Study NCT01854632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIL Live Attenuated Influenza Vaccine
Description: Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
Study NCT01854632 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
Study NCT03746600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project TRAC: Tracking and Reducing Alcohol Consumption
Description: The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
Study NCT03746600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project TRAC: Tracking and Reducing Alcohol Consumption
Description: The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
Study NCT01069159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Hydrochloride
Description: The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
Study NCT01069159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
Study NCT03736993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional blood sampling
Description: Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
Study NCT00790868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: 50mg
Study NCT00790868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50mg
Study NCT00743574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
Study NCT00743574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Study NCT01450436 — intervention group
Intervention type: OTHER
Intervention: Peapod assessment
Description: EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old).
Study NCT02483520 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FamTechCare
Description: Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
Study NCT02483520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamTechCare
Description: Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
Study NCT01405599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
Study NCT04353076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
Study NCT04353076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure with mid-day cooling
Description: Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
Study NCT01102400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
Study NCT01125865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS insertion
Description: Self-expandable metallic stent will be inserted for malignant hilar obstruction.
Study NCT01125865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLS insertion
Description: DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
Study NCT06036667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 28Fr coaxial smart drain chest tube
Description: To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies.
Study NCT00193154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774
Description: 150mg PO, days 1-28, cycle repeated every 28 days
Study NCT00193154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
Study NCT01029795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599506
Description: Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
Study NCT01029795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Administered po, BID daily prior to morning and evening meals for 12 weeks
Study NCT01029795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
Study NCT01029795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
Study NCT04056689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL151
Description: Oral repeating dose
Study NCT04056689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral repeating dose
Study NCT02692716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For oral use once daily.
Study NCT02692716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For oral use once daily.
Study NCT05445986 — intervention group
Intervention type: PROCEDURE
Intervention: flap elevation and guided bone regeneration
Description: to rebuild the alveolar ridge convexity
Study NCT05445986 — intervention group
Intervention type: PROCEDURE
Intervention: gap filling
Description: to use biomaterials to fill the jumping gap
Study NCT05445986 — intervention group
Intervention type: PROCEDURE
Intervention: connective tissue graft
Description: to change the soft tissue phenotype by connective tissue graft
Study NCT03830476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance- and Commitment therapy group for parents to children with disabilities
Description: ACT groups adjusted for parents of children with (any kind of) disabilities.
Study NCT03830476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual.
Description: Treatment as usual within outpatient disability services.
Study NCT01766063 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY 86-5046)
Description: Patients will be followed-up for 24 months
Study NCT05103579 — intervention group
Intervention type: DEVICE
Intervention: MindMics
Description: Patients rhythms was recorded using MindMics device
Study NCT01824654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Validation of the new rigid registration software
Description: Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
Study NCT01824654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Validation of the new elastic registration software
Description: This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
Study NCT01009437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I.
Study NCT01009437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Tissue collection is from all patients, including the control, phase I and phase II patients.
Study NCT01009437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Tissue collection is from all patients, including the control, phase I and phase II patients.
Study NCT04606199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention, up to 5 minutes 0-3 times/day
Description: The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
Study NCT02196883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection
Study NCT03596047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial wave therapy
Description: 6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
Study NCT03596047 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo therapy
Description: There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
Study NCT03727646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: nicotinamide riboside supplied as 250mg capsules
Study NCT05935878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Oxford Unicompartmental Knee Arthroplasty
Description: All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
Study NCT05935878 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Oxford Unicompartmental Knee Arthroplasty
Description: All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
Study NCT04920370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720 SC
Description: ALXN1720 will be administered via SC route.
Study NCT04920370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1720 IV
Description: ALXN1720 will be administered via IV route.
Study NCT04920370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered via SC route.
Study NCT04920370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo will be administered via SC route.
Study NCT04920370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo will be administered via IV route.
Study NCT02066870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
Study NCT02066870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved.
Study NCT01247740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuTRIflex Lipid peri
Description: parenteral nutrition
Study NCT01247740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: compounded monobag
Description: parenteral nutrition
Study NCT02908555 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a descriptive study with no intervention
Study NCT00399776 — intervention group
Intervention type: RADIATION
Intervention: Bone Density Test
Description: Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
Study NCT00637481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given orally
Study NCT00637481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies